Delivery Order SPE2DB24D2011-SPE2DB25FBRHQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of the contractor's pharmaceutical supply relationship with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $39,485.33 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 23, 2025, with ultimate completion by July 24, 2025. This firm fixed-price, non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a non-set-aside award made through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location. The delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $17,873.07 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 8, 2025, for XELJANZ XR 11 mg tablets (30-count packages). The award, which carries an ultimate completion date of August 11, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRHQDelivery Order
The Defense Logistics Agency awarded a $4,455.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units), with an ultimate completion date of July 21, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. The delivery order represents a child contract action under AmerisourceBergen's larger indefinite delivery contract with the Defense Logistics Agency. This award falls under AmerisourceBergen's comprehensive $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX) extending through December 2026, which serves as a global pharmaceutical support vehicle for military healthcare programs. The contract vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. XELJANZ XR is a branded immunosuppressant medication used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the types of specialized medications maintained within the company's federal pharmaceutical supply portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 7/18/25 |